Key Updates
Moderna shares kept falling, dropping another 2.32% to $24.04 since the last report and hitting new local lows amid the ongoing correction. The company began dosing patients in a Phase 1/2 study of the experimental T-cell therapy mRNA-2808 for multiple myeloma, a key step in expanding its oncology pipeline beyond traditional mRNA vaccines.
Current Trend
Moderna is in a steady downtrend across all time frames: –3.49% today, –5.17% week-to-date, –15.62% month-to-date and –12.93% six-month. The current price of $24.04 reflects continued pressure as COVID-vaccine demand wanes and investors weigh future earnings from new therapeutic lines.
Investment Thesis
The thesis for Moderna rests on its transformation from a COVID-vaccine maker into a diversified biotech platform focused on oncology, respiratory diseases and rare conditions. A core driver is the potential of mRNA technology to create personalized anti-cancer therapies and to move beyond preventive vaccines into therapeutic applications.
Thesis Status
The thesis remains mixed. Launching clinical trials for mRNA-2808 in multiple myeloma shows progress on the diversification strategy, but the ongoing share decline signals investor skepticism about commercialization timelines and the ability of new programs to offset falling COVID product revenues.
Key Drivers
The main positive catalyst is the launch of the Phase 1/2 study of mRNA-2808 for multiple myeloma, demonstrating progress in the oncology pipeline and T-cell therapy potential. However, the continued price drop highlights prevailing negative factors, including expectations of weak earnings and uncertainty around the timing of revenue from new therapeutic programs.
Technical Picture
Technically, Moderna shares are in a clear downtrend with key support levels broken. The $24.04 price sets new local minima, with no significant support nearby. Negative momentum across all horizons points to weak buying interest and the possibility of further declines toward historic lows.
Bull Case
- Start of clinical trials for mRNA-2808 in multiple myeloma shows progress in the oncology pipeline and T-cell therapy potential (Simply Wall St)
- Expanding the therapeutic pipeline beyond traditional vaccines creates new long-term revenue opportunities
- Current low valuation could offer an attractive entry point for long-term investors if the clinical programs succeed
- The mRNA platform can enable personalized anti-cancer therapies with high added value
- Diversification into oncology may provide more stable and predictable earnings compared with pandemic-driven products
Bear Case
- Ongoing share decline of –15.62% month-to-date reflects fundamental investor concerns about the company’s outlook
- Early-stage trials for mRNA-2808 carry high failure risk and long timelines to potential commercialization (Simply Wall St)
- Falling COVID-vaccine demand pressures current revenues without sufficient offset from new products
- Intense competition in oncology could limit the commercial upside of new developments
- Technical weakness with broken support levels suggests further price downside potential